CORDIS · 825359 · H2020
GLIOVACC Augmenting and broadening T-cell responses to glioblastoma - therapeutic vaccine platform based on HCMV expressing NKG2D ligands
Coordinator: SVEUCILISTE U RIJECI, MEDICINSKI FAKULTET (HR)
The development of an effective vaccine against human cancers is of tremendous importance. Glioblastoma multiforme (GBM) is the most malignant form of brain tumor with extremely poor survival. The human cytomegalovirus (HCMV) is involved in GBM pathogenesis suggesting that viral proteins might provide therapeutic targets. We propose a vaccination strategy against GBM based on a genetically modified HCMV that could target HCMV, as well as tumor specific antigens. The proposal builds on the successful implementation of the ERC-AdG StAdvInn, which investigates a murine cytomegalovirus (MCMV) exp…
About Horizon 2020 (2014–2020)
Horizon 2020 was the EU's flagship research and innovation programme for 2014–2020, with a budget of around €77 billion. It bundled FP7's strands with the EIT and the Competitiveness and Innovation Programme, introduced a stronger societal-challenge orientation, and pushed the funding logic toward closer-to-market innovation. New calls closed in 2020 but funded projects continued through 2024.
EU contribution: €150k awarded to the consortium. The project runs over approximately 1.7 years from 2018-12-01 to 2020-07-31.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu → Grant DOI ↗More from HR
see all →- MARBLE — Centre of Excellence in Maritime Robotics and Technologies for Sustainable Blue Economy101136349 · HORIZON · €15.0M
- ANEUPLOIDY — Molecular origins of aneuploidies in healthy and diseased human tissues855158 · H2020 · €10.0M
- InnoThyroGen — Innovating Thyroid Health with Genomics and Predictive Algorithms through Collaborative Excellence101187880 · HORIZON · €4.9M
- INNOMOL — Enhancement of the Innovation Potential in SEE through new Molecular Solutions in Research and Development316289 · FP7 · €4.7M
- GLOWBRAIN — Combining Stem Cells and Biomaterials for Brain Repair - Unlocking the Potential of the Existing Brain Research through Innovative In Vivo Molecular Imaging316120 · FP7 · €3.8M
- ACROSS — Centre of Research Excellence for Advanced Cooperative Systems285939 · FP7 · €3.4M
Other H2020 projects
see all →- EUROfusion — Implementation of activities described in the Roadmap to Fusion during Horizon 2020 through a Joint programme of the members of the EUROfusion consortium633053 · DE · €678.8M
- H2020 — COST at a turning point: A unique framework for pan-European ST cooperation as clear demonstration of European values681463 · BE · €178.2M
- HBP SGA3 — Human Brain Project Specific Grant Agreement 3945539 · BE · €150.0M
- COVID-19 VACCINES — PROPOSAL FOR FUNDING RESEARCH DEVELOPMENT AND MANUFACTURING OF VACCINE AGAINST COVID-19101018100 · NO · €100.0M
- UNITE4TB — ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS101007873 · NL · €92.5M
- ERA4TB — EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS853989 · ES · €89.8M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Horizon 2020 (2014–2020) programme, under the ERC-POC funding scheme.
- What is the EU contribution?
- The European Commission contributes €150k toward a total project budget of €150k.
- Which EU programme funds it?
- The project is funded under Horizon 2020 (2014–2020), call ERC-2018-PoC.
- Who coordinates the project?
- The project is coordinated by SVEUCILISTE U RIJECI, MEDICINSKI FAKULTET (HR).
- What is the project timeline?
- The project runs from 2018-12-01 to 2020-07-31 — approximately 1.7 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 825359.